Clinical Trial

A Study of AL102 in Patients With Progressing Desmoid Tumors

Study acronym: RINGSIDE
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
Protocol Amendment History 2 changes
critical Primary endpoint(s) modified 2026-06-09
minor Completion pushed: 2026-10 -> 2026-12 2026-06-09
Trial Details
NCT Number NCT04871282
Lead Sponsor Immunome, Inc.
Conditions Desmoid, Desmoid Tumor
Enrollment 198 participants
Start Date 2021-09-01
Primary Completion 2025-12-03 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-08